NextPlat (NASDAQ: NXPL), a global e-commerce provider, has released the voting results from its Special Annual Meeting of Stockholders, which was held Sept. 13, 2024. According to the report, shareholder voted on six agenda items, including a proposal to approve and adopt the merger agreement and plan of reorganization making Progressive Care Inc. (OTCQB: RXMD) a wholly owned subsidiary of the company. The proposal was approved, with an anticipated closing date of Oct. 1, 2024. The announcement noted that Progressive Care shareholders also approved the business combination at a special meeting of shareholders held Sept. 13, 2024.
Other items approved by shareholders included a proposal to approve the issuance of more than 20% of the company’s issued and outstanding shares of common stock in connection with the business combination, a proposal to elect eight board nominees to the company’s board of directors, a proposal to ratify the appointment of RBSM LLP as the company’s independent registered public accounting firm for the year, and proposal to approve the compensation of the company’s executive officers.
To view the full press release, visit https://ibn.fm/ix5d6
About NextPlat Corp
NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care. For more information about the company, please visit www.NextPlat.com.
NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN